check_circleStudy Completed
Multiple sclerosis
Bayer Identifier:
308272
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis
Trial purpose
The purpose of this follow-up study is to look carefully at the long-term course of multiple sclerosis (MS) and possibly the long-term effects of Betaseron in the patients who were previously enrolled in the original North American study that led to the marketing approval of Betaseron.
Key Participants Requirements
Sex
BothAge
33 YearsTrial summary
Enrollment Goal
432Trial Dates
January 2005 - December 2005Phase
N/ACould I Receive a placebo
NoProducts
Betaseron (Interferon beta-1b, BAY86-5046)Accepts Healthy Volunteer
NoWhere to participate
Status | Institution | Location |
---|---|---|
Completed | Many Locations, Canada | |
Completed | Many Locations, Canada | |
Completed | Many Locations, Canada | |
Completed | Many Locations, United States | |
Completed | Many Locations, United States | |
Completed | Many Locations, United States | |
Completed | Many Locations, United States | |
Completed | Many Locations, United States | |
Completed | Many Locations, United States |
Primary Outcome
- Description of long term course of diseasedate_rangeTime Frame:16 yearsenhanced_encryptionNoneSafety Issue:
Secondary Outcome
- Comparison to natural history cohortdate_rangeTime Frame:16 yearsenhanced_encryptionNoneSafety Issue:
Trial design
Trial Type
ObservationalIntervention Type
DrugTrial Purpose
N/AAllocation
N/ABlinding
N/AAssignment
N/ATrial Arms
N/A